Shots:

• Calliditas to receive $24M upfront and is eligible to receive ~$91M as regulatory and commercialization milestones along with royalties on net sales
• The companies collaborated to develop a new oral formulation that downregulates IgA1 by combining Calliditas' drug-delivery expertise with STADA's extensive marketing and sales platform for specialty and nephrology therapies
• The companies collaborated to bring a specialty therapy for IgAN in EU market- If approved- the therapy would be available to EU patients in H1’22 & would be the first approved treatment in the EU for chronic autoimmune kidney disease IgAN

| Ref: PR Newswire | Image: Pharmaceutical Technology